Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study

Several cytogenetic abnormalities are associated with poor outcomes in multiple myeloma (MM). We prospectively analyzed the impact of cytogenetic abnormalities on outcomes during the phase 2 PX-171-003-A1 study of single-agent carfilzomib for relapsed and refractory MM. In the response-evaluable pop...

Descripción completa

Detalles Bibliográficos
Autores principales: Jakubowiak, A J, Siegel, D S, Martin, T, Wang, M, Vij, R, Lonial, S, Trudel, S, Kukreti, V, Bahlis, N, Alsina, M, Chanan-Khan, A, Buadi, F, Reu, F J, Somlo, G, Zonder, J, Song, K, Stewart, A K, Stadtmauer, E, Harrison, B L, Wong, A F, Orlowski, R Z, Jagannath, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3865533/
https://www.ncbi.nlm.nih.gov/pubmed/23670297
http://dx.doi.org/10.1038/leu.2013.152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3865533/
https://www.ncbi.nlm.nih.gov/pubmed/23670297
http://dx.doi.org/10.1038/leu.2013.152

Ejemplares similares